Citation
Surowy, Carol S., et al. "(R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-evoked Firing of Spinal Dorsal Horn Neurons in Vivo." The Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 3, 2008, pp. 879-88.
Surowy CS, Neelands TR, Bianchi BR, et al. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther. 2008;326(3):879-88.
Surowy, C. S., Neelands, T. R., Bianchi, B. R., McGaraughty, S., El Kouhen, R., Han, P., Chu, K. L., McDonald, H. A., Vos, M., Niforatos, W., Bayburt, E. K., Gomtsyan, A., Lee, C. H., Honore, P., Sullivan, J. P., Jarvis, M. F., & Faltynek, C. R. (2008). (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. The Journal of Pharmacology and Experimental Therapeutics, 326(3), 879-88. https://doi.org/10.1124/jpet.108.138511
Surowy CS, et al. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-evoked Firing of Spinal Dorsal Horn Neurons in Vivo. J Pharmacol Exp Ther. 2008;326(3):879-88. PubMed PMID: 18515644.
TY - JOUR
T1 - (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
AU - Surowy,Carol S,
AU - Neelands,Torben R,
AU - Bianchi,Bruce R,
AU - McGaraughty,Steve,
AU - El Kouhen,Rachid,
AU - Han,Ping,
AU - Chu,Katharine L,
AU - McDonald,Heath A,
AU - Vos,Melissa,
AU - Niforatos,Wende,
AU - Bayburt,Erol K,
AU - Gomtsyan,Arthur,
AU - Lee,Chih-Hung,
AU - Honore,Prisca,
AU - Sullivan,James P,
AU - Jarvis,Michael F,
AU - Faltynek,Connie R,
Y1 - 2008/05/30/
PY - 2008/6/3/pubmed
PY - 2008/9/30/medline
PY - 2008/6/3/entrez
SP - 879
EP - 88
JF - The Journal of pharmacology and experimental therapeutics
JO - J Pharmacol Exp Ther
VL - 326
IS - 3
N2 - The transient receptor potential vanilloid (TRPV) 1 receptor, a nonselective cation channel expressed on peripheral sensory neurons and in the central nervous system, plays a key role in pain. TRPV1 receptor antagonism is a promising approach for pain management. In this report, we describe the pharmacological and functional characteristics of a structurally novel TRPV1 antagonist, (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), which has entered clinical trials. At the recombinant human TRPV1 receptor ABT-102 potently (IC(50) = 5-7 nM) inhibits agonist (capsaicin, N-arachidonyl dopamine, anandamide, and proton)-evoked increases in intracellular Ca(2+) levels. ABT-102 also potently (IC(50) = 1-16 nM) inhibits capsaicin-evoked currents in rat dorsal root ganglion (DRG) neurons and currents evoked through activation of recombinant rat TRPV1 currents by capsaicin, protons, or heat. ABT-102 is a competitive antagonist (pA(2) = 8.344) of capsaicin-evoked increased intracellular Ca(2+) and shows high selectivity for blocking TRPV1 receptors over other TRP receptors and a range of other receptors, ion channels, and transporters. In functional studies, ABT-102 blocks capsaicin-evoked calcitonin gene-related peptide release from rat DRG neurons. Intraplantar administration of ABT-102 blocks heat-evoked firing of wide dynamic range and nociceptive-specific neurons in the spinal cord dorsal horn of the rat. This effect is enhanced in a rat model of inflammatory pain induced by administration of complete Freund's adjuvant. Therefore, ABT-102 potently blocks multiple modes of TRPV1 receptor activation and effectively attenuates downstream consequences of receptor activity. ABT-102 is a novel and selective TRPV1 antagonist with pharmacological and functional properties that support its advancement into clinical studies.
SN - 1521-0103
UR - https://www.unboundmedicine.com/medline/citation/18515644/_R___5_tert_butyl_23_dihydro_1H_inden_1_yl__3__1H_indazol_4_yl__urea__ABT_102__blocks_polymodal_activation_of_transient_receptor_potential_vanilloid_1_receptors_in_vitro_and_heat_evoked_firing_of_spinal_dorsal_horn_neurons_in_vivo_
L2 - http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=18515644
DB - PRIME
DP - Unbound Medicine
ER -